Chelation therapy with desferrioxamine (DFO) can be an important problem fo
r patients with thalassaemia major (TM). In an effort to find a solution to
this problem, a new delivery system based on a disposable and lightweight
device was developed by Baxter. The aim of study was to investigate the com
pliance of patients and the effects and side effects of two different infus
ors. The 26 patients using infusors were divided into 2 groups, who were in
fused with DFO for 48 h (group A) and for 120 h (group B). The 24-h mean ur
inary iron and zinc excretion in groups A and B were statistically signific
ant at the beginning and end of therapy (p < 0.001). Serum ferritin levels
decreased in both groups compared with control (p < 0.001). No systemic rea
ctions were observed either during or at the end of treatment. The complian
ce and use of infusors were 97% in group A and 72% in group B. In conclusio
n, better compliance was achieved and there were fewer local complications
in group A than in group B. Subcutaneous infusion of DFO with both devices
may be ideal for patients who have compliance problems and cannot be treate
d using portable pumps. The device is new and expensive, but excellent and
effective for long-term DFO infusion.